Zura Bio (ZURA) reported second-quarter 2026 financial results and corporate updates, including a net loss of $26.3 million, or $0.21 per share, compared with a net loss of $16.0 million, or $0.17 per share, in the same period of 2025.
The company said it had $205.1 million in cash and cash equivalents as of June 30, 2026, which it expects to fund planned operations through at least the end of 2028.
- TibuSHIELD enrollment in hidradenitis suppurativa is complete with 247 participants randomized, and topline data are expected in Q4 2026.
- TibuSURE enrollment in systemic sclerosis is complete with 91 participants randomized, and topline data are expected in H1 2027.
- Zura plans to initiate a Phase 2 study of tibulizumab in polymyalgia rheumatica by year-end 2026.
- Second-quarter R&D expenses were $20.7 million, compared with $8.7 million a year earlier.
- Second-quarter G&A expenses were $8.6 million, compared with $9.4 million a year earlier.
$ZURA Insider Trading Activity
$ZURA insiders have traded $ZURA stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ZURA stock by insiders over the last 6 months:
- BIOTECHNOLOGY LLC AI purchased 2,000,000 shares for an estimated $12,500,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ZURA Hedge Fund Activity
We have seen 57 institutional investors add shares of $ZURA stock to their portfolio, and 33 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SUVRETTA CAPITAL MANAGEMENT, LLC added 3,500,000 shares (+62.9%) to their portfolio in Q1 2026, for an estimated $20,825,000
- COMMODORE CAPITAL LP added 3,250,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $19,337,500
- BLACKROCK, INC. added 3,157,336 shares (+690.3%) to their portfolio in Q2 2026, for an estimated $18,628,282
- SIREN, L.L.C. added 2,434,866 shares (+187.3%) to their portfolio in Q1 2026, for an estimated $14,487,452
- CORMORANT ASSET MANAGEMENT, LP added 1,450,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $8,627,500
- QVT FINANCIAL LP added 1,310,593 shares (+inf%) to their portfolio in Q1 2026, for an estimated $7,798,028
- ECOR1 CAPITAL, LLC added 1,179,715 shares (+inf%) to their portfolio in Q1 2026, for an estimated $7,019,304
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
